<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631603</url>
  </required_header>
  <id_info>
    <org_study_id>StopEAA</org_study_id>
    <nct_id>NCT02631603</nct_id>
  </id_info>
  <brief_title>Stop Exogenous Allergic Alveolitis (EAA) in Childhood</brief_title>
  <acronym>chILD-EU_EAA</acronym>
  <official_title>Stop Exogenous Allergic Alveolitis (EAA) in Childhood: Healthy Into Adulthood - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prednisolone Treatment and Course of Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Griese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood - a randomized,&#xD;
      double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and&#xD;
      course of disease.&#xD;
&#xD;
      The hypothesis of the study is that the treatment with placebo will not be inferior in terms&#xD;
      of Forced Vital Capacity (FVC) improvement than treatment with systemic steroids after 6&#xD;
      months treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be allocated to the two treatments, i.e., oral prednisolone and Placebo.&#xD;
&#xD;
      Experimental intervention: Placebo Control intervention: Prednisolone Duration of&#xD;
      intervention per patient: 3 months Follow-up per patient: 3 months&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate outcome of EAA at 6 months and compare the medium term treatment with systemic&#xD;
      steroids or Placebo.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To evaluate the completeness and knowledge of standardized and pedantic allergen elimination&#xD;
      in families with a child with EAA.&#xD;
&#xD;
      To evaluate the treatment of EAA with systemic steroids compared to placebo at 3 months.&#xD;
&#xD;
      To evaluate the safety of the treatment of EAA with outpatient usage of systemic steroids&#xD;
      compared to Placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    funding pending&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The relative change from baseline through month 6 compared to change from placebo for forced vital capacity (FVC).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each patient will be classified as a responder or non-responder. A patient is considered as a responder, if the FVC value after 6 months is more than or equal to 93% of the norm values tabulated by Quanjer PH., et al. 2013</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (FVC)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desaturation with standardized exercise test for children</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg scale</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of care in €</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight for height (%)</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Calculated from current weight * 100 / weight median for height of subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open usage of rescue glucocorticosteroids (mg/kg/6 months)</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Allergic Alveolitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules of placebo will be taken for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral prednisolone, anticipated dose:&#xD;
first month after steroid pulse 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose.&#xD;
Individual capsules will be prepared using rounded dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administer Placebo as anti-inflammatory</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Administer Prednisolone as anti-inflammatory</description>
    <arm_group_label>Prednisolone</arm_group_label>
    <other_name>Decortin H</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly or previously diagnosed but not appropriately treated EAA in children,&#xD;
             adolescents and young adults, aged between 3 and 25 years. The diagnosis of EAA must&#xD;
             be confirmed by independent review of the findings by an expert panel and must be&#xD;
             based on the presence of at least 4 of the following findings:&#xD;
&#xD;
               -  History of appropriate allergen exposure&#xD;
&#xD;
               -  Restrictive lung function (FVC &lt; 80% predicted for age and FVC/FEV1 &lt; 1) testing,&#xD;
                  if appropriate for age (usually &gt; 5 y)&#xD;
&#xD;
               -  Positive serum precipitins for bird/fungus exposed to (other allergens have&#xD;
                  rarely, if every been demonstrated in children)&#xD;
&#xD;
               -  Lymphocytosis in BAL (&gt; 20% of cells are lymphocytes)&#xD;
&#xD;
               -  HRCT showing the characteristic nodular, linear or reticular opacities, and&#xD;
                  ground glass pattern with increased attenuation.&#xD;
&#xD;
               -  Lung biopsy demonstrating lymphocytic alveolitis, bronchiolitis, and&#xD;
                  non-caseating histiocytic granulomatas.&#xD;
&#xD;
               -  Controlled allergen exposure followed by characteristic reaction, including&#xD;
                  fever, coughing, restriction on lung function, hypoxemia/desaturation at rest or&#xD;
                  with exercise&#xD;
&#xD;
          2. Unchanged inhaled steroids if on; if off, no plans to introduce them in the following&#xD;
             6 months&#xD;
&#xD;
          3. Agreement to home visit by independent study physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication for usage systemic steroids&#xD;
&#xD;
          2. Critically ill patients needing respiratory support&#xD;
&#xD;
          3. Non-compliance with medical treatments and interventions&#xD;
&#xD;
          4. Women with childbearing potential and not practicing a medically accepted&#xD;
             contraception during the trial and a positive pregnancy test (serum or urine) before&#xD;
             and at the end of the trial. Reliable contraception are systematic contraceptives&#xD;
             (oral, implant, injection) and diaphragm or condoms with spermicide.&#xD;
&#xD;
          5. Pregnancy and lactation.&#xD;
&#xD;
          6. Participation in another trial for EAA during the last 4 weeks or not beyond the time&#xD;
             of 4 half-lives of the medication used. In the unlikely event a subject is already in&#xD;
             another clinical study but not for EAA, that study must be stopped and the subject may&#xD;
             be treated according to this protocol; a latency time between the two studies does not&#xD;
             appear reasonable, as acute intervention is necessary for EAA. Treatment may be best&#xD;
             done in the frame work of this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Griese, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians-University Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meike Hengst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians University Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Universität München, Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum im St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Essen, Pädiatrische Pneumologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik u. Poliklinik für Kinder- u. Jugendmedizin der Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Matthias Griese</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alveolitis, Extrinsic Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

